This company has been marked as potentially delisted and may not be actively trading. Cesca Therapeutics (KOOL) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsDividendOwnershipTrendsBuy This Stock KOOL vs. THMO, AMWL, RPID, SEER, CCLD, CRBP, LUCD, SAVA, CGTX, and SPROShould you be buying Cesca Therapeutics stock or one of its competitors? The main competitors of Cesca Therapeutics include ThermoGenesis (THMO), American Well (AMWL), Rapid Micro Biosystems (RPID), Seer (SEER), CareCloud (CCLD), Corbus Pharmaceuticals (CRBP), Lucid Diagnostics (LUCD), Cassava Sciences (SAVA), Cognition Therapeutics (CGTX), and Spero Therapeutics (SPRO). These companies are all part of the "medical" sector. Cesca Therapeutics vs. Its Competitors ThermoGenesis American Well Rapid Micro Biosystems Seer CareCloud Corbus Pharmaceuticals Lucid Diagnostics Cassava Sciences Cognition Therapeutics Spero Therapeutics Cesca Therapeutics (NASDAQ:KOOL) and ThermoGenesis (NASDAQ:THMO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, profitability, valuation, risk, institutional ownership and dividends. Do institutionals and insiders hold more shares of KOOL or THMO? 3.1% of Cesca Therapeutics shares are held by institutional investors. Comparatively, 5.8% of ThermoGenesis shares are held by institutional investors. 68.9% of Cesca Therapeutics shares are held by insiders. Comparatively, 78.0% of ThermoGenesis shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has more risk & volatility, KOOL or THMO? Cesca Therapeutics has a beta of 1.07, meaning that its stock price is 7% more volatile than the S&P 500. Comparatively, ThermoGenesis has a beta of 1.18, meaning that its stock price is 18% more volatile than the S&P 500. Is KOOL or THMO more profitable? ThermoGenesis has a net margin of 0.00% compared to Cesca Therapeutics' net margin of -98.84%. ThermoGenesis' return on equity of 0.00% beat Cesca Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cesca Therapeutics-98.84% -77.30% -37.75% ThermoGenesis N/A N/A N/A Does the media favor KOOL or THMO? In the previous week, Cesca Therapeutics' average media sentiment score of 0.00 equaled ThermoGenesis'average media sentiment score. Company Overall Sentiment Cesca Therapeutics Neutral ThermoGenesis Neutral Which has stronger valuation & earnings, KOOL or THMO? ThermoGenesis has lower revenue, but higher earnings than Cesca Therapeutics. Cesca Therapeutics is trading at a lower price-to-earnings ratio than ThermoGenesis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCesca Therapeutics$9.67M3.08-$39.72M-$3.60-3.42ThermoGenesis$9.61M0.00-$17.98M-$5.14N/A SummaryThermoGenesis beats Cesca Therapeutics on 8 of the 10 factors compared between the two stocks. Get Cesca Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KOOL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KOOL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KOOL vs. The Competition Export to ExcelMetricCesca TherapeuticsLaboratory Apparatus & Furniture IndustryMedical SectorNASDAQ ExchangeMarket Cap$29.75M$1K$5.76B$9.72BDividend Yield0.50%N/A4.40%4.10%P/E Ratio-3.42N/A30.1925.84Price / Sales3.080.00474.98187.82Price / CashN/AN/A25.7828.79Price / Book3.96N/A9.425.99Net Income-$39.72M-$17.98M$3.27B$265.29M Cesca Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KOOLCesca TherapeuticsN/A$12.32+1.3%N/A+15.2%$29.75M$9.67M-3.4253THMOThermoGenesisN/AN/AN/AN/A$1K$9.61M0.0040AMWLAmerican Well2.951 of 5 stars$7.14-1.6%$9.17+28.5%-20.6%$117.10M$269.78M-0.881,040RPIDRapid Micro Biosystems3.6548 of 5 stars$2.46-7.2%$8.00+225.2%+239.3%$116.15M$28.05M-2.44200Analyst DowngradeSEERSeer0.5347 of 5 stars$2.04-0.5%N/A+31.1%$115.50M$14.17M-1.47160CCLDCareCloud2.0922 of 5 stars$2.72flat$2.50-8.1%-2.1%$115.12M$110.84M-68.003,650News CoveragePositive NewsCRBPCorbus Pharmaceuticals4.4886 of 5 stars$9.13-1.3%$49.00+436.7%-83.6%$113.36MN/A-1.9240Positive NewsLUCDLucid Diagnostics2.9155 of 5 stars$0.99-2.6%$3.55+257.3%+34.3%$110.65M$4.35M-0.8470Positive NewsInsider TradeGap UpSAVACassava Sciences2.5053 of 5 stars$2.19-3.5%$2.00-8.7%-92.9%$109.66MN/A-0.8630Positive NewsCGTXCognition Therapeutics1.6268 of 5 stars$1.67+12.1%$2.83+69.7%+280.8%$109.47MN/A-2.4920Positive NewsGap UpSPROSpero Therapeutics3.9344 of 5 stars$1.84-3.7%$5.00+171.7%+36.5%$107.49M$47.98M-1.88150News Coverage Related Companies and Tools Related Companies THMO Alternatives AMWL Alternatives RPID Alternatives SEER Alternatives CCLD Alternatives CRBP Alternatives LUCD Alternatives SAVA Alternatives CGTX Alternatives SPRO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KOOL) was last updated on 8/25/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cesca Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Cesca Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access